Multiple Myeloma: Targeting BCMA in the Heavily Pretreated Population
Advertisement
Advertisement
Trending on CancerNetwork
1
TIP127 TroFuse-012: A Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab Vs Treatment of Physician’s Choice in Participants With Triple-Negative Breast Cancer who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery
2
FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC
3
Achieving a “Functional Cure” With Multiple Myeloma Therapy
4
Epigenetic Priming and Immunotherapy Synergy Across the Lymphoma Space
5